Krystal Biotech (KRYS) Interest Expenses (2016 - 2026)
Krystal Biotech (KRYS) posted quarterly Interest Expenses of $475.4 million for Q2 2026, up 305.85% year-over-year from $117.1 million in Q2 2025, and up 66.17% on a QoQ basis from $286.1 million in Q1 2026.
Krystal Biotech (KRYS) Interest Expenses (2016 - 2026) Analysis & Trends
Krystal Biotech has reported Interest Expenses for 11 years, with the latest figure at $475.4 million in Q2 2026.
- Interest Expenses for Q2 2026 came in at $475.4 million, up 305.85% year-over-year; the trailing twelve-month figure through Jun 2026 was $475.4 million (up 305.85% YoY), and the FY2025 annual result was $298.7 million, up 90.96% from the prior year.
- Interest Expenses grew to $475.4 million in Q2 2026, from $286.1 million in the prior quarter.
- Over five years, Interest Expenses peaked at $475.4 million in Q2 2026 and troughed at $28.3 million in Q2 2022.
- A 5-year average of $176.1 million and a median of $169.1 million in 2023 frame the typical range for Interest Expenses.
- The widest annual swing landed in 2023, when Interest Expenses soared 496.74%; it then tumbled 46.65% in 2025.
- A 5-year view of Interest Expenses shows it stood at $37.2 million in 2022, then jumped by 304.17% to $150.4 million in 2023, then rose by 3.99% to $156.4 million in 2024, then jumped by 90.96% to $298.7 million in 2025, then soared by 59.18% to $475.4 million in 2026.
- Per Business Quant data, the three most recent Interest Expenses figures were $475.4 million in Q2 2026, $286.1 million in Q1 2026, and $298.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn | 475.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 475.42 Mn |
| Jun 30, 2026 | 475.42 Mn |
| Mar 31, 2026 | 286.11 Mn |
| Mar 31, 2026 | 286.11 Mn |
| Dec 31, 2025 | 298.66 Mn |
| Dec 31, 2025 | 298.66 Mn |
| Sep 30, 2025 | 180.42 Mn |
| Sep 30, 2025 | 180.42 Mn |
| Jun 30, 2025 | 117.14 Mn |
| Jun 30, 2025 | 117.14 Mn |
| Mar 31, 2025 | 198.81 Mn |
| Mar 31, 2025 | 198.81 Mn |
| Dec 31, 2024 | 156.40 Mn |
| Dec 31, 2024 | 156.40 Mn |
| Sep 30, 2024 | 209.85 Mn |
| Sep 30, 2024 | 209.85 Mn |
| Jun 30, 2024 | 219.58 Mn |
| Jun 30, 2024 | 219.58 Mn |
| Mar 31, 2024 | 236.28 Mn |
| Mar 31, 2024 | 236.28 Mn |